Welcome back to the plenary session podcast.

I'm going to be giving you the real plenary session.

This time it's Adyra, Adjuvant, Osamertinib, the AstraZeneca study.

In the next few days, I'm going to be bringing you videos on the number of the biggest abstracts that hit at Asco.

But I got to start with Adora because the cheerleaders are out there in full force and we finally have what many

of us has been speculating about for the last three years, information about subsequent therapy

in the Adora study. It really matters when it comes to overall survival. We'll walk you through

that. Let's take a look. This is entitled Overall Survival with Assymeritnib and Resected EGFR

mutant non-small cell lung

cancer. It's the Adora trial. We all know this space. Prior to Adora, we had in 2017,

the results of Flora. Flora shows that upfront osamartinib has an improved PFS over Githinib

and Erlatinib. It has better brain penetration, and it quickly became the standard of care in places

that could afford osomeratinib. It was the de facto frontline metastatic drug for EGFR mutation

positive, L8-58R, and Exxon 19, non-small cell lung cancer. That's what it was. It was the primary

standard of care upon metastasis. Now, the authors want to grab that big, sweet, sweet market share of

the adjuvant space, okay? And that's what this trial is. It's the AstraZeneca effort to get

the adjuvant market share from 1B all the way to three. And that means more money for

AstraZeneca because you can put a lot more people on the drug, people who are resected,

and it's okay to give them more money if they

show that the routine upfront use of adjuvant osmary is superior to the standard of care,

which is Aussie upon progression when you have metastatic disease. That's what this trial is all

about. So let's take a look, the Adora trial. People love the hazard ratio. The first time it came around, I think

...